Abstract Library

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,

#693 Histopathological Reporting of Neuroendocrine Tumors: A 4-Year Tertiary Referral Centre Experience

Introduction: Histopathological recognition of neuroendocrine tumors (NETs) is straightforward, however, sub-classification, grading and staging is challenging with frequently evolving pathological criteria.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Karpathakis A, Miki Y, Thirlwell C, Meyer T, Toumpanakis C,

Keywords: histopathology, Ki-67, staging,

#226 Insulin-like Growth Factor-1 Receptor (IGF-1R) and its Inhibition in Non-functioning Neuroendocrine Tumors

Introduction: Insulin-like growth factor-1 receptor (IGF-1R) was reported to be expressed in NET (neuroendocrine tumor) cells but its biological roles and activation status in non-functioning NET are unknown.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Sasano H, Iida S, Ono K, Nakamura Y, Miki Y,

Keywords: IGF-1R, mTOR, non-functioning neuroendocrine tumor, immunohistochemistry,

#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors

Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Sasano H

Authors: Iida S, Miki Y, Ono K, Sasano H,

Keywords: neuroendocrine tumors, mTOR inhibitors, MEK inhibitors, combination therapy,